| Market Cap | 305.74M | P/E | 3.16 | EPS this Y | 96.10% | Ern Qtrly Grth | - |
| Income | -345.11M | Forward P/E | 8.87 | EPS next Y | 66.70% | 50D Avg Chg | -6.00% |
| Sales | 132.19M | PEG | -0.27 | EPS past 5Y | -32.03% | 200D Avg Chg | 11.00% |
| Dividend | N/A | Price/Book | 1.20 | EPS next 5Y | 25.00% | 52W High Chg | -32.00% |
| Recommedations | 2.00 | Quick Ratio | 1.39 | Shares Outstanding | 95.34M | 52W Low Chg | 161.00% |
| Insider Own | 2.47% | ROA | -3.01% | Shares Float | 84.30M | Beta | 0.80 |
| Inst Own | 39.35% | ROE | -178.62% | Shares Shorted/Prior | 6.23M/6.22M | Price | 5.41 |
| Gross Margin | 72.13% | Profit Margin | -261.08% | Avg. Volume | 1,817,154 | Target Price | 3.15 |
| Oper. Margin | -17.73% | Earnings Date | Nov 6 | Volume | 1,645,490 | Change | 0.56% |
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
| Maxim Group | Buy | Jul 26, 24 |
| HC Wainwright & Co. | Buy | Jul 3, 24 |
| Alliance Global Partners | Buy | May 28, 24 |
| Lake Street | Buy | Mar 12, 24 |
| BWS Financial | Buy | Nov 3, 23 |
| BWS Financial | Buy | Aug 4, 23 |
| Lake Street | Buy | May 10, 23 |
| BWS Financial | Buy | May 10, 23 |
| BWS Financial | Buy | Mar 3, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schlessinger Sam | SVP, General Counsel SVP, General Counsel | Sep 11 | Sell | 3.0383 | 45,236 | 137,441 | 69,038 | 09/13/23 |
| Patel Ajay | SVP and CAO SVP and CAO | Sep 11 | Sell | 3.0444 | 64,313 | 195,794 | 93,643 | 09/13/23 |
| Schwichtenberg Paul | SVP and CFO SVP and CFO | Sep 11 | Sell | 3.0729 | 104,980 | 322,593 | 64,313 | 09/13/23 |
| Peisert Daniel A. | President & CEO President & CEO | Sep 11 | Sell | 3.01 | 158,402 | 476,790 | 324,939 | 09/13/23 |
| MCKEE WILLIAM | Director Director | May 10 | Sell | 3.1384 | 22,000 | 69,045 | 238,780 | 08/15/23 |
| Mason Heather L | Director Director | May 19 | Sell | 7.3025 | 89,286 | 652,011 | 187,650 | 05/22/23 |
| Tyree James L | Director Director | May 05 | Sell | 5.9979 | 43,143 | 258,767 | 167,308 | 05/05/23 |
| Tyree James L | Director Director | May 12 | Sell | 2.3558 | 44,643 | 105,170 | 210,451 | 05/16/22 |
| MCKEE WILLIAM | Director Director | May 12 | Sell | 2.3514 | 22,322 | 52,488 | 229,586 | 05/16/22 |
| Peisert Daniel A. | President and CEO President and CEO | Apr 11 | Sell | 3.50 | 26,391 | 92,368 | 158,402 | 04/13/22 |
| Peisert Daniel A. | President and CEO President and CEO | Apr 05 | Sell | 3.50 | 34,518 | 120,813 | 184,793 | 04/07/22 |